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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or 
not aprepitant is effective in preventing postoperative nausea and vomiting. 
 
STUDY DESIGN: Review of three English language primary randomized controlled 
trials from 2012-2014. 
 
DATA SOURCES: Three double-blind, randomized controlled trials comparing oral 
aprepitant with placebo. All articles were found using PubMed. 
 
OUTCOMES MEASURED: The three studies measured nausea severity using a verbal 
rating system and number of episodes of nausea and vomiting recorded by a blinded 
study investigator. 
 
RESULTS: Vallejo et al found that 29.7% of the patients in the placebo group vomited 
compared to 9.3% of the patients who received aprepitant (p = 0.003). They also found 
that the worst VRS nausea score was a 5 out of 10 in the group of patients who received 
aprepitant versus 8 out of 10 for the placebo group (p = 0.014). Jung et al found that the 
groups that received aprepitant had a 35% incidence of nausea compared to 63% in the 
placebo group (p = 0.0025). In addition, the aprepitant groups both had 0% incidence of 
vomiting compared to the placebo group, which had a 20% incidence (p = 0.005). Sinha 
et al found that incidence of vomiting at 72 hours was 3.1% in the experimental group 
and 15.0% in the placebo group (p = 0.021). In all of the studies, mean VRS nausea 
scores were lower but were not found to be statistically significant. 
 
CONCLUSIONS: Aprepitant is effective in preventing incidence of nausea and 
vomiting, but is not found to significantly decrease average nausea rating scores. 
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INTRODUCTION 
 
Postoperative nausea and vomiting (PONV) is one of the most common 
complications after undergoing surgery with general anesthesia1. Symptoms can range 
from mild nausea to multiple episodes of severe vomiting. This can be distressing to 
patients and may result in electrolyte imbalances, dehydration, and hypovolemia2. 
Extensive retching and vomiting can also lead to other severe complications such as 
aspiration, gastric bleeding, and wound hematomas3. In addition, PONV can delay oral 
intake of drugs, fluids, and food4. 
Studies have shown that PONV negatively impacts quality of life, and results in 
delayed recovery after surgery4. This can lead to prolonged stay in the post-anesthesia 
care unit (PACU) or even hospital admission. Prolonged hospital stays only add to the 
already expensive cost of surgery, as well as being distressing to the patient and 
increasing morbidity5. A single episode of nausea and/or vomiting costs about $22 in 
addition to the extra costs associated with a longer hospital stay.  
PONV can affect up to 30% of patients undergoing general anesthesia, and this 
number can reach up to 80% if the patient has risk factors such as female gender, opioid 
use, or non-smoking status1. In addition, longer duration of anesthesia also increases risk 
of PONV6.  
It is thought that the cause of PONV is multifactorial. Two of the main causes 
include opioid induced emesis and inhalational anesthesia induced emesis4. There are 
many neurotransmitters involved in this process such as 5-HT, dopamine, and 
neurokinin-1 (NK1)4. These neurotransmitters have receptors in the chemoreceptor 
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trigger zone in the brain, and imbalances can result in nausea and vomiting in the 
postoperative period4.  
 Antiemetic medications are used before or during surgery to prevent PONV. The 
serotonin receptor antagonist ondansetron is most commonly used. Histamine receptor 
antagonists including dimenhydrinate and promethazine and dopamine receptor 
antagonists including metoclopramide are also used. Dexamethasone, a corticosteroid, is 
less commonly used but can also be successful. Non-medical treatment includes 
acupuncture6. While these agents are all effective, there is not one medication that works 
universally for all patients1.  
A new class of antiemetics, NK1 receptor antagonists, has emerged in recent 
years and has been used in preventing nausea and vomiting both in postoperative as well 
as chemotherapy patients. They work by blocking substance P from binding at the NK1 
receptors in the dorsal vagal complex and area postrema, which are both central emetic 
pathways7. Aprepitant is currently the only NK1 receptor antagonist on the market and 
currently it is mostly being used for chemotherapy-induced nausea and vomiting. It has a 
half life of 9 to 12 hours, which makes it longer acting than the more commonly used 
serotonin receptor antagonists8. Adverse effects are mild and may include fatigue, 
diarrhea, or dizziness9.  
 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not 
aprepitant is effective in preventing postoperative nausea and vomiting.  
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METHODS 
 This paper evaluates three double blind randomized control trials comparing 
efficacy of aprepitant as a medication for improving nausea and vomiting in patients 
postoperatively. All three studies were chosen using the same criteria. The population 
included patients that have undergone surgery with general anesthesia and the 
interventions included 40, 80, or 125 mg of oral aprepitant. All three studies used patients 
who had at least 2 of the following risk factors for PONV: female gender, nonsmoker, 
history of motion sickness or previous PONV, and use of postoperative opioids. The 
treatment group receiving aprepitant was compared an experimental group which 
received a placebo. The outcomes measured were the effect of aprepitant on the incidence 
of nausea and vomiting as well as the effect of aprepitant on the severity of nausea. 
Finally, all three trials were randomized, double blind clinical trials. 
 All articles were written in English and published in peer reviewed journals. They 
were selected from Pubmed in 2015 by the author using the keywords “aprepitant” and 
“postoperative nausea and vomiting.” The articles were chosen based on relevance and 
that the outcomes of the studies were patient oriented (POEMs). Inclusion criteria 
included randomized, double blind controlled trials with patients over the age of 18 and 
exclusion criteria included articles published before 1996 and patients that did not 
undergo general anesthesia. All articles were published between 2012 and 2014 and have 
similar demographics and characteristics (Table 1). The statistics reported or used in the 
studies were control event rate (CER) and experimental event rate (EER), relative risk 
reduction (RRR), absolute risk reduction (ARR), number needed to treat (NNT), odds 
ratio (OR), and p-value.  
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Table 1. Demographics & Characteristics of included studies 
 
Study Type # Pts Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W/D Interventions 
Vallejo 
(2012)1 
Double 
blind 
RCT 
150 18-65 
years 
Patients 18-65 
years with 
American Society 
of Anesthesiology 
(ASA) 1 to III 
status who are 
considered high 
risk for PONV 
and were 
undergoing 
ambulatory 
plastic surgery 
under general 
anesthesia for at 
least 1-hour  
Patient refusal, 
received other 
antiemetics before 
procedure, history 
of allergy or 
sensitivity to study 
drugs, pregnancy, 
history of chronic 
opioid use 
1 40 mg of oral 
aprepitant plus 
4 mg of IV  
ondansetron or 
oral placebo 
plus 4 mg of 
IV  
ondansetron 
 
Jung 
(2013)7 
Double 
blind 
RCT 
123 21-60 
years 
Patients 21-60 
years considered 
high risk for 
PONV scheduled 
for elective 
laparoscopic total 
hysterectomy 
with ASA I to II 
status 
Liver, neurologic, 
and active 
pulmonary disease, 
cardiac 
arrhythmia, 
allergies to any 
perioperative 
medications used 
in the study 
0 Preoperative 
80 mg oral 
aprepitant; pre 
Operative 125 
mg oral   
aprepitant; or 
placebo (10 
mL saline)  
Sinha 
(2014)8 
Double 
blind 
RCT 
125 18 
years 
or 
older 
Patients over 18 
years considered 
high risk for 
PONV who are 
morbidly obese 
and undergoing 
elective 
gastrointestinal 
surgery with ASA 
I to III status 
Allergy to 
ondansetron or 
aprepitant, 
pregnant or 
breastfeeding, 
substance abuse or 
significant 
psychiatric 
disease, history of 
chronic 
nausea/vomiting, 
taking any 
medication with 
known antiemetic 
properties or 
known interaction 
with study drugs 
1 80 mg oral 
aprepitant and 
4 mg 
ondansetron or 
placebo tablet 
 and 4 mg 
ondansetron 
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OUTCOMES MEASURED 
 All three studies measured the severity of nausea as well as the incidence of 
nausea and vomiting. Severity of nausea was measured by the patient using a verbal 
rating scale (VRS) where 0 represented no nausea and 10 represented worst possible 
nausea. Incidence of nausea and vomiting was measured by a blinded study investigator. 
In the study by Vallejo et al, patients also recorded incidence of nausea and vomiting at 
home once they were discharged from the hospital1. All of the studies considered patients 
to have a complete response if they had no nausea, retching, or vomiting during the 
postoperative period. 
 
RESULTS 
 Vallejo et al enrolled 150 patients between the ages of 18 and 65 with American 
Society of Anesthesiology (ASA) I to III status who were undergoing plastic surgery with 
general anesthesia and had 2 or more risk factors for PONV1. Exclusion criteria included 
patient refusal, receiving other antiemetics before procedure, history of allergy or 
sensitivity to study drugs, pregnancy, and history of chronic opioid use. Patients either 
received 40 mg of oral aprepitant plus 4 mg of intravenous ondansetron or oral placebo 
plus 4 mg intravenous ondansetron. The aprepitant or placebo was administered within 2 
hours before the procedure, and the ondansetron was administered at the start of 
anesthesia. One patient was lost to follow up after discharge, but their results in the 
hospital were still included in analysis. Patients rated their nausea severity every 4 hours 
for the first 24 hours after surgery, and then every 8 hours the second 24 hours. 
Occurrence of vomiting was recorded hourly until discharge. Intention-to-treat analysis 
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was performed. They found that 29.7% of the patients in the placebo group vomited 
compared to 9.3% of the patients who received aprepitant (p = 0.003) with a risk 
reduction of 31.3% (95% CI, 14.3-69.0%) In addition, they found that all of the episodes 
of vomiting occurred in the first 12 hours after surgery. They also found that the worst 
VRS nausea score, defined as the highest score reported by the patient in the 48 hours, 
was a 5 out of 10 in the group of patients who received aprepitant versus 8 out of 10 for 
the placebo group (p = 0.014). The mean VRS nausea scores were also higher in the 
placebo group, however it was not significant (p = 0.24). Complete response occurred in 
26 patients in the experimental group and 20 patients in the control group but this was 
also not significant (p=0.288)1.  
 Statistical analysis of incidence of vomiting for all three RCTs can be found in 
table 2. For the study conducted by Vallejo et al, relative risk reduction (RRR) was found 
to be -69.0%, and absolute risk reduction (ARR) was found to be -20.4%. Number 
needed to treat (NNT) was calculated to be -4. This means that for every 4 patients 
treated with aprepitant, one fewer patient vomited than if they had received the placebo. 
 Jung et al selected patients age 21-65 years with ASA status I or II undergoing 
elective laparoscopic total hysterectomy7. Patients were also considered high risk for 
PONV, using the same criteria as Vallejo et al. Exclusion criteria included liver, 
neurologic, and active pulmonary disease, cardiac arrhythmia, and allergies to any 
perioperative medications used in the study. Patients were randomly divided into three 
groups of 40 and either received 80 mg aprepitant, 125 mg aprepitant, or 10 mL normal 
saline as placebo. The aprepitant or placebo was administered 2 hours before anesthesia. 
Patients were assessed at 2 hours, 24 hours, and 48 hours, and any episodes of nausea and 
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vomiting were recorded throughout that time period. Both of the groups that received 
aprepitant had a 35% incidence of nausea compared to 63% in the placebo group (p = 
0.0025). In addition, the aprepitant groups both had 0% incidence of vomiting compared 
to the placebo group, which had a 20% incidence (p = 0.005). The difference between the 
80 mg and 125 mg aprepitant groups was not significant. The peak VRS nausea scores 
were 6 out of 10 for the placebo group, and 4 out of 10 in both aprepitant groups, but this 
data is not statistically significant. Complete response during the first 48 hours after 
surgery was seen in 28% of the control group, 56% of the 80 mg aprepitant group, and 
63% of the 125 mg aprepitant group. Both 80 mg and 125 mg aprepitant groups were 
found to be significantly higher than the control group (p = 0.007 and p = 0.004 
respectively)7.  
 For the study conducted by Jung et al, RRR was found to be -100.0%, and ARR 
was found to be -20.0%. NNT was calculated to be -5. This means that for every 5 
patients treated with aprepitant, one fewer patient vomited than if they had received the 
placebo. 
 Jung et al also recorded the incidence of adverse effects. Patients in all three 
groups reported adverse effects including dizziness, headache, dyspepsia, and abdominal 
distension. The symptoms were all mild and no patients required additional treatment. 
There was no statistical significance of incidence of adverse effects between control and 
experimental groups7.   
Sinha et al enrolled 125 patients aged 18 years or above, were morbidly obese, 
ASA status I to III, and considered high risk for PONV8. Exclusion criteria included 
allergy to ondansetron or aprepitant, pregnant or breastfeeding, substance abuse or 
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significant psychiatric disease, history of chronic nausea/vomiting, and taking any 
medication with known antiemetic properties or known interaction with study drugs. One 
patient was lost from the placebo group during surgery. Patients either received 80 mg 
oral aprepitant and 4 mg IV ondansetron or placebo tablet and 4 mg IV ondansetron. The 
aprepitant tablet or placebo tablet was administered 1 hour before surgery, and IV 
ondansetron was administered to every patient just before the end of surgery. Nausea 
severity scores were recorded during the postoperative period at 3 minutes, 1, 2, 6, 24, 
48, and 72 hours. Any episode of vomiting was also recorded. Incidence of vomiting at 
72 hours was 3.1% in the group that received aprepitant, which was significantly lower 
than the placebo group which had an incidence of 15.0% (p = 0.021, 95% CI, 5.67-
24.30%). The odds ratio (OR) of an episode of vomiting in the control group compared to 
the experimental group was 5.47 times (p = 0.026, 95% CI, 1.31-26.46). The results for 
mean VRS nausea scores were not statistically significant. Complete response was seen 
in 27 patients (42.18%) in the experimental group and in 22 patients (36.67%) in the 
control group, but this was also not statistically significant (p = 0.510)8.  
 For the study conducted by Sinha et al, RRR was found to be -79.3%, and ARR 
was found to be -11.9%. NNT was calculated to be -8. This means that for every 8 
patients treated with aprepitant, one fewer patient vomited than if they had received the 
placebo. 
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Table 2. Statistical Analysis of Oral Aprepitant vs. Placebo Effect on Incidence of 
Vomiting 
Study Control 
Event 
Rate 
(CER) 
Experimental 
Event Rate 
(EER) 
Relative Risk 
Reduction 
(RRR) 
Absolute 
risk 
reduction 
(ARR) 
Number 
Needed to 
Treat 
(NNT) 
Vallejo et al 
(2012)1 
29.7% 9.3% -69.0% -20.4% -4 
Jung et al 
(2013)7 
20.0% 0.0% -100% -20% -5 
Sinha et al 
(2014) 
15.0% 3.1% -79.3% -11.9% -8 
 
DISCUSSION 
 All three studies showed a significant decrease in the incidence of postoperative 
vomiting with oral aprepitant compared to placebo. In addition, Jung et al also showed a 
significant decrease in the incidence of nausea with aprepitant. Peak nausea rating score 
was significantly higher as reported by Vallejo et al, although the other studies failed to 
get significant results. Mean VRS nausea scores appeared to decrease with aprepitant, but 
none of the studies had statistically significant results.   
 The main limitation of the use of aprepitant is the cost. Since it is a newer drug, it 
is substantially more expensive than the older, more commonly used agents. Vallejo et al 
reported that the cost of aprepitant at their institution was $46.60 compared to $0.60 for 
ondansetron1. While aprepitant is considerably more costly than ondansetron, it must be 
considered that an extended hospital stay and extra care required for patients with severe 
nausea and vomiting postoperatively could incur an even higher cost. Patients would 
likely be willing to pay the extra cost of aprepitant to avoid the potential complications 
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that can result from extensive episodes of vomiting and extra costs associated with a 
longer stay at the hospital. 
 There are also some limitations of the studies themselves. Vallejo et al reports that 
a limitation of their study was the timing of the administration of ondansetron1. Previous 
studies show that ondansetron is most effective when given near the end of surgery1. In 
this study, the ondansetron was given at the beginning of surgery to account for the 
variation in surgery duration between patients1. Jung et al did not study doses of 
aprepitant less than 80 mg7. In addition, they did not calculate a cost-effectiveness 
analysis7. Finally, Sinha et al reports that they did not compare opioid between the 
control and experimental groups8. Since opioids increase risk of nausea and vomiting, 
this could have affected the results.  
 
CONCLUSION 
Based on this systematic review of three randomized controlled trials, aprepitant 
is effective in preventing the incidence of nausea and vomiting; however it is not shown 
to be significantly effective in reducing the severity of nausea if it occurs. Even though 
the cost may present a problem for some patients, aprepitant has the potential to reduce 
postoperative complications from excessive vomiting and lead to shorter hospital stays. 
This not only reduces overall cost, but could also improve quality of life in patients 
during the postoperative period. Future studies should be focused toward comparing 
aprepitant to the commonly used antiemetics for PONV such as ondansetron or 
metoclopramide. In addition, it would be also advantageous to investigate the use of 
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aprepitant for other causes of nausea and vomiting since it is effective and has mild 
adverse effects.
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